Issues influencing neurology patient groups in 2023 PatientView’s 2024 report, Patients in Action, examines how patient groups, including those specialising in neurological conditions, view their roles in national healthcare systems. Findings from this survey, which included responses from neurology-focused groups, were compared with 19 other therapeutic areas, revealing key insights into neurology patient groups’ perspectives…
Long COVID hits younger and middle-aged adults hardest
Since older adults have been more severely affected by acute COVID-19, researchers have hypothesised that older adults may have worse long COVID symptoms as well. However, new research published in the Annals of Neurology, an official journal of the American Neurological Association, found that, on average, 10 months after COVID-19 onset, younger (ages 18–44) and…
Phase 2 LRRK2 inhibitor trial in early PD
19 November, 2024: Neuron23 Inc. has announced the Phase 2 NEULARK clinical trial of NEU-411, a brain-penetrant LRRK2 inhibitor, targeting early-stage Parkinson’s disease (PD). The trial employs precision medicine strategies, focusing on individuals with LRRK2-driven PD, who may represent up to 30% of the PD population. This population includes those with familial LRRK2 mutations and…
Motor neuron disease: gene therapy protective in rats
Via Newswise, 12 November 2024: University of Wisconsin–Madison researchers targeting a group of hereditary neurodegenerative diseases have found success using a gene therapy treatment in an animal model. The approach, which uses CRISPR-Cas9 genome editing technology, offers a strategy that could one day treat motor neuron diseases in humans. Hereditary spastic paraplegia, or HSP, is…
Finger-prick blood test accurately detects p-tau217
A pilot study presented at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference highlights the potential of a finger-prick blood test to measure p-tau217, a key biomarker for Alzheimer’s disease (AD). The study demonstrated a strong correlation between p-tau217 levels from capillary dried plasma spot (DPS) samples and standard venous plasma. Capillary samples, collected…
Understanding Tourette syndrome
Tourettes Action have created a new e-learning module, Understanding Tourette syndrome for GPs. This course has been created with the help of Dr Kate Szymankiewicz, a GP with an interest in Tourette syndrome and clinical experts from the Tourettes Action Board of Trustees. In this module, you will learn what Tourette syndrome is, co-occurring features…
EMA reverses decision on Leqembi (lecanemab)
14 November 2024: The EMA has today partially approved a marketing application for Leqembi (Biogen/Eisai), having previously rejected it it July 2024, saying that the side effects outweighed the benefits. “After re-examining its initial opinion, the EMA… has recommended granting marketing authorisation to Leqembi (lecanemab) for treating mild cognitive impairment or mild dementia due to…
Laura Benjamin is awarded the Federick Murgatroyd Prize
Congratulations to Dr Laura Benjamin who has been awarded the Federick Murgatroyd Prize. The Federick Murgatroyd Prize is awarded to medical graduates who have made an important contribution to the science or practice of tropical medicine. Laura is a Principal Clinical Research Fellow at The MRC Laboratory of Molecular and Cell Biology, UCL and an…
Sarah Tabrizi elected to the US National Academy of Medicine
Congratulations to Professor Sarah Tabrizi who has recently been elected to the US National Academy of Medicine. Sarah is Professor of Clinical Neurology at University College London, UK, Honorary Consultant Neurologist, Director of UCL Huntington’s Disease Centre, and Joint Head of Department of Neurodegenerative Disease. Election to the Academy is considered one of the highest…
